Your browser doesn't support javascript.
loading
Mechanism of action and treatment of type I interferon in hepatocellular carcinoma
Peng, Chunxiu; Ye, Zhijian; Ju, Ying; Huang, Xiuxin; Zhan, Chenjie; Wei, Ke; Zhang, Zhiyong.
Affiliation
  • Peng, Chunxiu; Guangxi Medical University. Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy. Guangxi Key Laboratory of Bio-targeting Theranostics. Guangxi. China
  • Ye, Zhijian; Guangxi Medical University. Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy. Guangxi Key Laboratory of Bio-targeting Theranostics. Guangxi. China
  • Ju, Ying; Guangxi Medical University. Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy. Guangxi Key Laboratory of Bio-targeting Theranostics. Guangxi. China
  • Huang, Xiuxin; Guangxi Medical University. Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy. Guangxi Key Laboratory of Bio-targeting Theranostics. Guangxi. China
  • Zhan, Chenjie; Guangxi Medical University. Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy. Guangxi Key Laboratory of Bio-targeting Theranostics. Guangxi. China
  • Wei, Ke; Guangxi Medical University. Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy. Guangxi Key Laboratory of Bio-targeting Theranostics. Guangxi. China
  • Zhang, Zhiyong; Guangxi Medical University. Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy. Guangxi Key Laboratory of Bio-targeting Theranostics. Guangxi. China
Clin. transl. oncol. (Print) ; 26(2): 326-337, feb. 2024.
Article in En | IBECS | ID: ibc-230179
Responsible library: ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Hepatocellular carcinoma (HCC) caused by HBV, HCV infection, and other factors is one of the most common malignancies in the world. Although, percutaneous treatments such as surgery, ethanol injection, radiofrequency ablation, and transcatheter treatments such as arterial chemoembolization are useful for local tumor control, they are not sufficient to improve the prognosis of patients with HCC. External interferon agents that induce interferon-related genes or type I interferon in combination with other drugs can reduce the recurrence rate and improve survival in HCC patients after surgery. Therefore, in this review, we focus on recent advances in the mechanism of action of type I interferons, emerging therapies, and potential therapeutic strategies for the treatment of HCC using IFNs (AU)
Subject(s)
Key words
Search on Google
Add to My VHL
Print
XML

Collection: 06-national / ES Database: IBECS Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Journal: Clin. transl. oncol. (Print) Year: 2024 Document type: Article
Search on Google
Add to My VHL
Print
XML

Collection: 06-national / ES Database: IBECS Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Journal: Clin. transl. oncol. (Print) Year: 2024 Document type: Article